A Registry Study of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in Japan

Inclusion Criteria:

• Must have a confirmed diagnosis of palmoplantar pustulosis (PPP) and/or pustuloticarthro-osteitis (PAO) in accordance with local clinical practice

• Has previously been prescribed treatment for PPP/PAO

• A decision has been made by the treating physician and the participant to commencetreatment with a systemic PPP/PAO therapy, having been deemed to have an inadequateresponse to previous therapy (New users are defined as those participants tocommence treatment on baseline visit date. Existing users are defined as those whocommenced treatment prior to the baseline visit since 01 November 2019.)

• Must sign a participation agreement/informed consent form allowing data collectionand source data verification in accordance with local requirements

Exclusion Criteria:

• Are receiving, or have received within the past 3 months, anti-inflammatory oranalgesic systemic therapy such as oral corticosteroid, disease modifyingantirheumatic drug (DMARDs), non-steroidal anti-inflammatory drugs, opioids,phosphodiesterase 4 (PDE4) inhibitor, or biologics for any other indication (forexample, psoriasis, rheumatoid arthritis, ankylosing spondylitis, psoriaticarthritis, and asthma)

• Received an investigational drug (including investigational vaccines) or used aninvasive investigational medical device within 3 months before the start of thestudy or the first data collection time point

• Participation in an investigational study

• Participation in another observational study for guselkumab (including a postmarketing surveillance study)

• If the only treatment they have received for PPP has been antibiotics